These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33985455)

  • 21. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.
    De Vita F; Ventriglia J; Febbraro A; Laterza MM; Fabozzi A; Savastano B; Petrillo A; Diana A; Giordano G; Troiani T; Conzo G; Galizia G; Ciardiello F; Orditura M
    BMC Cancer; 2016 Sep; 16(1):709. PubMed ID: 27590845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial.
    Zhang W; Du C; Sun Y; Yang L; Cui C; Jiang Z; Wang C; Wang J; Zhou A
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):655-660. PubMed ID: 30054709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.
    Macarulla T; Pazo-Cid R; Guillén-Ponce C; López R; Vera R; Reboredo M; Muñoz Martin A; Rivera F; Díaz Beveridge R; La Casta A; Martín Valadés J; Martínez-Galán J; Ales I; Sastre J; Perea S; Hidalgo M
    J Clin Oncol; 2019 Jan; 37(3):230-238. PubMed ID: 30523758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study.
    Takano N; Yamada S; Hirakawa A; Yokoyama Y; Kawashima H; Maeda O; Okada T; Ohno E; Yamaguchi J; Ishikawa T; Sonohara F; Suenaga M; Takami H; Hayashi M; Niwa Y; Hirooka Y; Ito Y; Naganawa S; Ando Y; Nagino M; Goto H; Fujii T; Kodera Y
    Nagoya J Med Sci; 2019 May; 81(2):233-239. PubMed ID: 31239592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Open-label, Phase I Study of Nivolumab Combined with
    Wainberg ZA; Hochster HS; Kim EJ; George B; Kaylan A; Chiorean EG; Waterhouse DM; Guiterrez M; Parikh A; Jain R; Carrizosa DR; Soliman HH; Lila T; Reiss DJ; Pierce DW; Bhore R; Banerjee S; Lyons L; Louis CU; Ong TJ; O'Dwyer PJ
    Clin Cancer Res; 2020 Sep; 26(18):4814-4822. PubMed ID: 32554514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
    Lowery MA; Yu KH; Kelsen DP; Harding JJ; Bomalaski JS; Glassman DC; Covington CM; Brenner R; Hollywood E; Barba A; Johnston A; Liu KC; Feng X; Capanu M; Abou-Alfa GK; O'Reilly EM
    Cancer; 2017 Dec; 123(23):4556-4565. PubMed ID: 28832976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
    Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer.
    Blomstrand H; Scheibling U; Bratthäll C; Green H; Elander NO
    BMC Cancer; 2019 Jan; 19(1):40. PubMed ID: 30621618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma (R/BR-PDAC)?
    Yamada D; Kobayashi S; Takahashi H; Iwagami Y; Akita H; Asukai K; Shimizu J; Yamada T; Tanemura M; Yokoyama S; Tsujie M; Asaoka T; Takeda Y; Morimoto O; Tomokuni A; Doki Y; Eguchi H
    Ann Surg Oncol; 2024 Jul; 31(7):4702-4703. PubMed ID: 38722422
    [No Abstract]   [Full Text] [Related]  

  • 32. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
    Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M
    J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study.
    Cohen SJ; O'Neil BH; Berlin J; Ames P; McKinley M; Horan J; Catalano PM; Davies A; Weekes CD; Leichman L
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):693-701. PubMed ID: 26886016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicentre, single-arm, phase II trial (ICSBR) protocol.
    Zhang C; Yang H; Chang C; Li R; Xiong J; Kang D; He D; Liu XJ; Cheng K; Cao D
    BMJ Open; 2024 Jul; 14(7):e084274. PubMed ID: 39013651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
    Ng K; Hendifar A; Starodub A; Chaves J; Yang Y; Koh B; Barbie D; Hahn WC; Fuchs CS
    Invest New Drugs; 2019 Feb; 37(1):159-165. PubMed ID: 30105668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact.
    Kondo N; Uemura K; Sudo T; Hashimoto Y; Sumiyoshi T; Okada K; Seo S; Otsuka H; Murakami Y; Takahashi S
    Eur J Cancer; 2021 Dec; 159():215-223. PubMed ID: 34781169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine.
    Sonbol MB; Ahn DH; Goldstein D; Okusaka T; Tabernero J; Macarulla T; Reni M; Li CP; O'Neil B; Van Cutsem E; Bekaii-Saab T
    Future Oncol; 2019 Apr; 15(12):1295-1302. PubMed ID: 30768369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer.
    Zhang DS; Wang DS; Wang ZQ; Wang FH; Luo HY; Qiu MZ; Wang F; Li YH; Xu RH
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):1065-72. PubMed ID: 23483298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis.
    Takahara N; Nakai Y; Ishigami H; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Yamashita H; Isayama H; Seto Y; Koike K
    Invest New Drugs; 2021 Feb; 39(1):175-181. PubMed ID: 32772340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.
    O'Reilly EM; Roach J; Miller P; Yu KH; Tjan C; Rosano M; Krause S; Avery W; Wolf J; Flaherty K; Nix D; Ryan DP
    Oncologist; 2017 Dec; 22(12):1429-e139. PubMed ID: 29158367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.